Parametric Portfolio Associates LLC lifted its holdings in shares of Celgene Co. (NASDAQ:CELG) by 7.9% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 2,236,649 shares of the biopharmaceutical company’s stock after acquiring an additional 163,486 shares during the period. Parametric Portfolio Associates LLC’s holdings in Celgene were worth $206,756,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also bought and sold shares of CELG. Archford Capital Strategies LLC raised its position in shares of Celgene by 277.8% during the 1st quarter. Archford Capital Strategies LLC now owns 272 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 200 shares during the last quarter. Liberty Wealth Management LLC lifted its stake in shares of Celgene by 212.8% in the 2nd quarter. Liberty Wealth Management LLC now owns 294 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 200 shares during the period. Weaver Consulting Group acquired a new position in shares of Celgene in the 1st quarter valued at $29,000. Alera Investment Advisors LLC lifted its stake in shares of Celgene by 109.9% in the 1st quarter. Alera Investment Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 167 shares during the period. Finally, Mizuho Securities Co. Ltd. bought a new position in shares of Celgene in the 1st quarter worth $31,000. 72.51% of the stock is owned by institutional investors and hedge funds.
Celgene stock traded up $0.55 during mid-day trading on Wednesday, hitting $98.20. 1,046,714 shares of the company’s stock were exchanged, compared to its average volume of 2,991,092. The firm has a market capitalization of $68.80 billion, a P/E ratio of 12.90, a PEG ratio of 0.45 and a beta of 1.41. Celgene Co. has a fifty-two week low of $58.59 and a fifty-two week high of $98.97. The company has a quick ratio of 3.32, a current ratio of 3.44 and a debt-to-equity ratio of 1.97. The company’s 50 day simple moving average is $94.75 and its 200-day simple moving average is $93.33.
Celgene (NASDAQ:CELG) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $2.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.44 by $0.17. Celgene had a return on equity of 89.93% and a net margin of 32.24%. The firm had revenue of $4.40 billion during the quarter, compared to analysts’ expectations of $4.22 billion. During the same period in the previous year, the firm earned $2.16 earnings per share. The company’s revenue was up 15.4% on a year-over-year basis. Research analysts expect that Celgene Co. will post 9.96 EPS for the current year.
A number of brokerages recently commented on CELG. BidaskClub cut Celgene from a “buy” rating to a “hold” rating in a research note on Saturday. ValuEngine lowered Celgene from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 1st. Cowen restated a “hold” rating and set a $102.00 target price on shares of Celgene in a report on Tuesday, July 30th. Mizuho lowered Celgene from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $103.00 to $100.00 in a research report on Monday, August 19th. Finally, Zacks Investment Research upgraded Celgene from a “sell” rating to a “hold” rating and set a $94.00 target price for the company in a research report on Tuesday, July 23rd. One analyst has rated the stock with a sell rating, eighteen have assigned a hold rating and three have given a buy rating to the company. Celgene currently has an average rating of “Hold” and a consensus price target of $94.60.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Story: Average Daily Trade Volume – ADTV
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.